34
Participants
Start Date
March 31, 1999
Primary Completion Date
December 31, 1999
Study Completion Date
December 31, 1999
liraglutide
Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
liraglutide
Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
placebo
Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
placebo
Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
Novo Nordisk Investigational Site, Manchester
Lead Sponsor
Novo Nordisk A/S
INDUSTRY